Earnings

Senseonics Lifts 2026 Revenue Outlook After Third Straight Raise

The Tip Desk · November 12, 2026 · 3 min read

Third-quarter revenue reached $19.6 million, and the company now sees full-year sales of $68 million to $70 million.

Senseonics Holdings (SENS), a diabetes company selling the Eversense 365 implantable glucose monitor, reported third-quarter 2026 revenue of $19.6 million, up approximately 140% from $8.1 million a year earlier, and raised its full-year revenue outlook for the third consecutive quarter.

The company now expects 2026 global net revenue of $68 million to $70 million, implying year-over-year growth of 93% to 98%, from a prior range of $62 million to $66 million. It also lifted full-year gross margin guidance to more than 60% from 58% to 61%.

Growth was about 140% in the third quarter, versus about 120% in the second quarter and 87% in the first. Sequential sales rose from $14.5 million in the second quarter. President and Chief Executive Officer Tim Goodnow said the approximately 140% increase reflected execution of the commercial strategy and rising awareness and demand for Eversense 365.

U.S. revenue was $16.8 million, up approximately 160% from $6.4 million a year earlier, on record quarterly shipment volume. Active prescribers were up approximately 90% year-over-year. U.S. sales had been $12.6 million in the second quarter, up more than 150% from a year earlier.

Revenue outside the United States was $2.8 million, up approximately 65% from $1.7 million in the year-ago period, after $1.9 million in the second quarter. Dedicated commercial teams are now leading Eversense 365 launches in European markets. Given the pace of U.S. outperformance, the company said it now expects revenue outside the United States to represent approximately 15% of full-year 2026 revenue. Its earlier outlook expected Europe to represent approximately 20% of full-year revenue.

Gross margin expanded to approximately 62% in the third quarter, with gross profit of $12.1 million, compared with 43% and $3.5 million of gross profit a year earlier. The margin had been approximately 59% in both the first and second quarters. Chief Commercial Officer Brian Hansen said recent investments in commercial infrastructure are expanding patient access, supporting growth and improving gross margins.

The EON Care network grew to more than 100 inserters, who performed over 40% of third-quarter Eversense insertion procedures. The company increased its year-end target for EON Care inserters to 120 from 100.

Net loss widened to $32.7 million, or $0.50 a share, from $19.5 million, or $0.43 a share, a year earlier. Selling, general and administrative expenses were $32.3 million, compared with $15.3 million, reflecting ongoing costs of the commercial organization in the U.S. and Europe. Research and development expenses were $11.7 million, compared with $7.8 million, reflecting clinical trial activity for Gemini and development work on Freedom.

As of September 30, 2026, cash, cash equivalents, restricted cash and short-term investments totaled $126.6 million. The carrying value of debt under the Hercules Capital facility was approximately $56.2 million, with $55.0 million in principal borrowings outstanding, consistent with the second quarter.

Senseonics announced a strategic partnership with Beta Bionics to integrate Eversense 365 with the iLet Bionic Pancreas automated insulin delivery system, with commercial launch planned for the fourth quarter of 2026, subject to completion of integration activities and applicable requirements. The company also initiated the first-in-human study of Freedom, an investigational next-generation CGM system designed to communicate directly with a mobile device without any on-body component.

The company said its outlook continues to reflect continued momentum in U.S. Eversense 365 growth, planned direct-to-consumer marketing investment, other sales and marketing initiatives, utilization of U.S. patient assistance programs, and the ongoing roll-out of Eversense 365 outside the United States.

More on SENS

September 28, 2026 QBook Stronger demand supports expansion as pricing diverges

Senseonics Holdings, Inc. — all coverage and financials